Trial Outcomes & Findings for Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery (NCT NCT00542542)

NCT ID: NCT00542542

Last Updated: 2015-04-13

Results Overview

Pain assessed using a verbal numeric rating scale (NRS) scored by numeric integers, with scores of 0-10 where 0 is no pain and 10 is the worst pain. Pain evaluated within the first hour, between 1 - 3 hours, between 3 - 6 hours post-operatively. Additional reporting planned for following morning (18 - 24 hours post-operatively).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

89 participants

Primary outcome timeframe

Starting immediately after surgery, every 2 hours till the 6th hour following surgery

Results posted on

2015-04-13

Participant Flow

Recruitment Period: September 10, 2007 to February 28, 2011. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.

Of the 89 participants enrolled, one participant was excluded prior to group assignment.

Participant milestones

Participant milestones
Measure
Group 1: Paravertebral Block + General Anesthesia
Paravertebral Block + General Anesthesia (Ropivacaine) Paravertebral Block: Paravertebral block given as a bolus injection into the paravertebral space. Ropivacaine: Ropivacaine given by injection into the paravertebral space along the spinal canal.
Group 2: General Anesthesia Alone
General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery.
Overall Study
STARTED
44
44
Overall Study
COMPLETED
44
44
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1: Paravertebral Block + General Anesthesia
n=44 Participants
Paravertebral Block + General Anesthesia (Ropivacaine) Paravertebral Block: Paravertebral block given as a bolus injection into the paravertebral space. Ropivacaine: Ropivacaine given by injection into the paravertebral space along the spinal canal.
Group 2: General Anesthesia Alone
n=44 Participants
General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery.
Total
n=88 Participants
Total of all reporting groups
Age, Continuous
49 years
n=5 Participants
51 years
n=7 Participants
51 years
n=5 Participants
Sex: Female, Male
Female
44 Participants
n=5 Participants
44 Participants
n=7 Participants
88 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
44 participants
n=5 Participants
44 participants
n=7 Participants
88 participants
n=5 Participants

PRIMARY outcome

Timeframe: Starting immediately after surgery, every 2 hours till the 6th hour following surgery

Population: Analysis was not possible from data collected due to reporting inconsistencies.

Pain assessed using a verbal numeric rating scale (NRS) scored by numeric integers, with scores of 0-10 where 0 is no pain and 10 is the worst pain. Pain evaluated within the first hour, between 1 - 3 hours, between 3 - 6 hours post-operatively. Additional reporting planned for following morning (18 - 24 hours post-operatively).

Outcome measures

Outcome data not reported

Adverse Events

Group 1: Paravertebral Block + General Anesthesia

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2: General Anesthesia Alone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Farzin Goravanchi, Professor, Anesthesiology & Perioperative Medicine

University of Texas MD Anderson Cancer Center

Phone: 713-563-5613

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place